Published in Biotech Business Week, May 3rd, 2004
The license will enable Adprotech to continue further development and commercialization of its APT070 product, which is currently in a clinical trial in rheumatoid arthritis. No rights to either of Avant's complement programs, TP10 and TP20, were transferred under the license. All rights to these two products remain fully owned worldwide by Avant.
Financial details of the agreement with Adprotech were not disclosed, but include...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.